We are live on ! Find out more
SVA

Sinovac Biotech, Ltd
SVA

Delisted

SVA was delisted on the 22nd of February, 2019.

Back to rankings

35 hedge funds and large institutions have $108M invested in Sinovac Biotech, Ltd in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

8% less funds holding

Funds holding: 38 → 35 (-3)

15% less capital invested

Capital invested by funds: $128M → $108M (-$19.8M)

31% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 13

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

Holders
35
Holders Change
-3
Holders Change %
-7.89%
% of All Funds
0.87%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
9
Reduced
13
Closed
8
Calls
$11K
Puts
–
Net Calls
+$11K
Net Calls Change
+$41K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$15.7M
2
Renaissance Technologies
Renaissance Technologies
New York
+$896K
3
GP
GLG Partners
United Kingdom
+$525K
4
Two Sigma Investments
Two Sigma Investments
New York
+$437K
5
Millennium Management
Millennium Management
New York
+$323K

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$31.9M
2
USAA
United Services Automobile Association
Texas
-$2.04M
3
Deutsche Bank
Deutsche Bank
Germany
-$402K
4
TC
TFS Capital
Pennsylvania
-$157K
5
FIM
Freedom Investment Management
Connecticut
-$111K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$14K +$11.5K +1,989 +389%
Group One Trading
27
Group One Trading
Illinois
$10K -$14.5K -2,500 -58%
Wells Fargo
28
Wells Fargo
California
$7K – – –
UBS Group
29
UBS Group
Switzerland
$6K -$4.55K -786 -44%
IA
30
IFP Advisors
Florida
$6K – – –
Creative Planning
31
Creative Planning
Kansas
$4K +$643 +111 +22%
JP Morgan Chase
32
JP Morgan Chase
New York
$3K -$4.93K -852 -60%
Carson Wealth (CWM LLC)
33
Carson Wealth (CWM LLC)
Nebraska
$3K – – –
LTFS
34
Ladenburg Thalmann Financial Services
Florida
$2K – – –
Citigroup
35
Citigroup
New York
$1K -$8.24K -1,424 -88%
USAA
36
United Services Automobile Association
Texas
– -$2.04M -346,215 Closed
TC
37
TFS Capital
Pennsylvania
– -$157K -26,662 Closed
GBBWRPM
38
Genovese Burford & Brothers Wealth & Retirement Plan Management
California
– -$59K -9,950 Closed
Simplex Trading
39
Simplex Trading
Illinois
– -$23K -4,003 Closed
TRCT
40
Tower Research Capital (TRC)
New York
– -$10K -1,607 Closed
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
– -$2K -338 Closed
VWM
42
Valley Wealth Managers
New Jersey
– -$1K -100 Closed
1
2

SVA Hedge Fund Activity: Q1 2017 in Review

35 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q1 2017, worth a combined $108M — down 15% from $128M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of SVA and 5 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 9 added.

The largest buyer was Morgan Stanley, adding an estimated $15.7M. The largest seller was Wellington Management Group, cutting an estimated $31.9M.

  • 35 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q1 2017, down from 38 in Q4 2016.
  • Funds reported $108M of Sinovac Biotech, Ltd stock for Q1 2017, down 15% quarter-over-quarter.
  • 5 funds opened new Sinovac Biotech, Ltd positions in Q1 2017 and 8 closed out, a net change of -3 holders.
  • The largest Sinovac Biotech, Ltd buyer in Q1 2017 was Morgan Stanley, an estimated $15.7M added.
  • The largest Sinovac Biotech, Ltd seller in Q1 2017 was Wellington Management Group, an estimated $31.9M sold.

Based on aggregated 13F filings for Q1 2017.